influenza branch division of viral and rickettsial diseases national center for infectious diseases...
TRANSCRIPT
Influenza BranchDivision of Viral and Rickettsial DiseasesNational Center for Infectious Diseases
Centers for Disease Control and PreventionAtlanta, GA 30333
Bethesda, MD
February 20, 2003
INFORMATION FOR THE VACCINES AND RELATED BIOLOGICALPRODUCTS ADVISORY COMMITTEE, CBER, FDA
WHO COLLABORATING CENTER FOR SURVEILLANCE,EPIDEMIOLOGY AND CONTROL OF INFLUENZA
U.S. SURVEILLANCE
WHO/NREVSS Collaborating Laboratories National Summary, 2002-03
0
100
200
300
400
500
40 42 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20
Week
Nu
mb
er
of
Iso
late
s
0
5
10
15
20
25
30
Pe
rce
nt
Po
sit
ive
A(H3N2)
A(H1N1) and A(H1N2)
A(Unsubtyped)
B
Percent Positive
Percentage of Visits for ILI Reported by Sentinel ProvidersNational Summary, 2002-03
0
1
2
3
4
5
6
40 42 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20
Week
% o
f V
isit
s f
or
ILI
Weekly Influenza Activity Estimates Reportedby State & Territorial Epidemiologists
No Report Sporadic Regional Widespread No Activity
Week ending February 8, 2003 - Week 6
Pneumonia and Influenza Mortality for 122 U.S. CitiesWeek Ending 02/08/03
4
6
8
10
12
Weeks
% o
f All
Dea
ths D
ue to
P&
I
1999 2000 2001 2002
“Epidemic” Threshold
Seasonal Baseline
10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10
2003
INFLUENZA A(H1) VIRUSES
HEMAGGLUTINATION INHIBITION REACTIONS OF INFLUENZA H1 VIRUSES
STRAIN DESIGNATION REFERENCE FERRET ANTISERAA B C D Date
REFERENCE ANTIGENS BJ/262 NC/20 HI/10 HI/15 collected Passage NA
1 A/BEIJING/262/95 640 320 320 40 01/09/95 E3/E3 N12 A/NEW CALEDONIA/20/99* 160 320 160 80 06/09/99 E4/E1 N13 A/HAWAII/10/2002 80 160 320 40 03/22/02 E3 N24 A/HAWAII/15/2001 20 40 20 160 02/17/01 M2/C3 N1
TEST ANTIGENS
5 A/MASSACHUSETTS/5/2002* 160 320 160 80 12/06/02 X/C1 N16 A/WISCONSIN/12/2002 160 640 320 160 12/03/02 C1/C1 N17 A/TEXAS/49/2002 160 320 160 80 11/25/02 M1/C1 N18 A/NEW JERSEY/05/2002 160 320 160 40 UNKN MX/C1 N19 A/CANADA/641/2002 320 320 640 40 11/20/02 X/C1 N210 A/CANADA/649/2002* 160 320 640 40 12/04/02 X/C1 N211 A/DELAWARE/01/2002 320 640 640 40 12/29/02 M2/C1 N212 A/PENNSYLVANIA/01/2003 640 640 1280 40 01/16/03 X/C1 N213 A/NEW YORK/01/2003 320 640 320 80 01/02/03 M1/C1 N114 A/NEW YORK/07/2003 320 640 640 40 01/07/03 X1/C1 N215 A/TEXAS/02/2003 80 320 160 80 01/05/03 M1/C1 N116 A/WASHINGTON/08/2002 160 320 1280 40 12/31/02 M1/C1 N217 A/MICHIGAN/208/2003 80 320 160 80 01/21/03 M1/C1 N118 A/MICHIGAN/236/2003 160 320 320 40 05/05/03 M1/C1 N219 A/PERU/3090/2002* 160 80 20 160 09/08/02 X/C1 N120 A/PERU/3064/2002 20 80 20 80 08/14/02 X/C1 N1
* Serology antigens
Influenza A(H1) Isolates Characterized by CDC
U.S.A. North America
Europe Asia Cent/So America
Africa, Australia,
New Zealand
Total (%)
April 2002 - September 2002
A/N.Caledonia/20/99-like 4 2 7 37 1 51 (76%)
A/N.Caledon./20/99-like (low) 2 14 16 (24%)
A/Johannesburg/82/96-like
Total 67
October 2002 - February 2003
A/N.Caledonia/20/99-like 47 9 1 57 (97%)
A/N.Caledon./20/99-like (low) 1 1 2 (3%)
A/Johannesburg/82/96-like
Total 59
Total 54 12 7 51 2 126
Preliminary Data 02/18/2003
Influenza A(H1N1) & A(H1N2) Isolates Identified by CDC
U.S.A. North America
Europe Asia Cent/So America
Africa, Australia,
New Zealand
Total (%)
April 2002 - September 2002
H1N1 5 2 9 51 1 68 (97%)
H1N2 1 1 2 (3%)
Total 70
October 2002 - March 2003
H1N1 61 1 3 1 66 (69%)
H1N2 21 9 30 (31%)
Total 96
Total 88 12 12 52 2 166
Preliminary Data 02/18/2003
Canada/649/2002*Michigan/2/2003
New York/3/2003Washington/8/2002
Canada/642/2002(LR)North Carolina/7/2002
Peru/3084/2002New York/2/2003Pennsylvania/1/2003
New York/26/2002Hawaii/10/2002#
South Dakota/2/2002Jilin/5/2002#
Florida/7/2002Peru/3090/2002(LR)*
Colombia/3575/2002Wuhan/6/2002
Neimongol/31/2002#Neimongol/43/2002#
Hong Kong/841/2002Alaska/1/2002Texas/49/2002
Hubei/18/2002(LR)#Sichuan/656/2002
Mexico/935/2002Wisconsin/12/2002
Guatemala/48/2002Texas/52/2002
Guizhou/198/2002Massachussetts/5/2002*
Oklahoma/3/2002Texas/1/2003
bafbKorea/1136/2002New Jersey/5/2002Michigan/1/2003
New York/1/2003Chile/10751/2002#
Chile/8196/2002#Chile/13309/2002#
Chile/8829/2002(LR)#nihjAkita/25/2002#
Chile/8885/2002(LR)#Alaska/3/2002
Arizona/13/2002Yamaguchi/12/2002
Georgia/8/2002Hawaii/15/2001(LR)
Russia/2187/2002(LR)#New Caledonia/20/99#*
E125bG, K166M
D275G
E82G
V169A
W255R
A193T, A218T, V178I
T96A
H1N
2
* serology antigen# egg isolate(LR) low reactor to A/New Caledonia/20/99vaccine strain
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA A(H1) HA1 GENES
NEURAMINIDASE INHIBITION TEST OF INFLUENZA N1 VIRUSES
STRAIN DESIGNATION FERRET ANTISERAA B C Date
REFERENCE ANTIGENS New Cal/20/99 Fuji/156/00 Neim/52/02 collected
1 A/New Caledonia/20/99 1280 1280 1280 06/09/992 A/Fujian/156/2000 1280 2560 1280 08/25/003 A/Neimonggu/52/2002 1280 2560 1280 01/25/024 A/Johannesburg/82/96 320 640 480 1996
TEST ANTIGENS
5 A/Colombia/3059/2002 1280 2560 2560 09/13/026 A/Guizhou/198/2002 2560 2560 1280 06/18/027 A/Wisconsin/12/2002 1280 1280 2560 12/03/028 A/Texas/48/2002 1280 1280 1280 11/14/02
NEURAMINIDASE INHIBITION TEST OF INFLUENZA N2 VIRUSES
STRAIN DESIGNATION FERRET ANTISERAA B C D Date
REFERENCE ANIGENS PN/2007/99 Chile/6416/01 HI/10/02 New Cal/20/99 collected
1 A/Panama/2007/99 (H3N2) 320 80 40 <10 07/12/992 A/Chile/6416/2001(H3N2) 160 320 80 <10 06/14/013 A/Shenzhen/499/2001(H3N2) 320 80 80 <10 05/22/004 A/Hawaii/10/2001(H1N2) 40 40 320 <10 03/22/025 A/New Caledonia/20/99 (H1N1) <10 <10 <10 1280 09/01/99
TEST ANIGENS
6 A/New York/28/2002 (H3N2) 320 320 120 <10 10/12/027 A/Fujian/411/2002 (H3N2) 160 160 80 <10 08/11/028 A/Peru/3084/2002 (H1N2) 80 80 320 <10 08/13/029 A/Canada/638/2002 (H1N2) 80 80 320 <10 11/19/02
Hong Kong/1252/2000Wuhan/251/2000#
Hong Kong/241/2000Wuhan/292/2000#
Russia/11/2001Shenzhen/201/2000#Hawaii/18/99
Fujian/156/2000#Hawaii/1/2000
Nanchang/8/2000#nimr-Hong Kong/1799/2000
Taiwan/1486/2001Hubei/288/2001*#
Hong Kong/747/2001*Brazil/821/2001*
Pusan/124/99New Caledonia/20/99*#
aus-New Caledonia/11/2000nimr-Ishikawa/42/98
Colorado/2/2001Hawaii/15/2001*
Bangkok/255/2001*#Washington/6/2001
nimr-Asuncion/1041/2000nimr-Brazil/202/2000
Bangkok/163/2000California/26/99
Peru/1261/99Peru/1798/99
nimr-Moscow/17/98nimr-Hong Kong/4859/98
Beijing/262/95New York/14/2000
Colorado/1/2001Chile/5255/2000
Chile/5724/2000nimr-Oslo/1734/98
Bayern/7/95Taiwan/1/86
V75IR222QD344N
D386N
Vaccine strain
*Serology Antigen# Egg isolate
10 nucleotides
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA A(N1) NA GENES
Summary: Influenza A(H1N1 and H1N2) Viruses
• Since last winter, H1N1 and H1N2 viruses have been reported primarily from the Americas (Canada, Chile and the U.S.).
• Most (>95%) of recent H1 viruses have HAs that are antigenically and genetically similar to that of the current vaccine strain, A/New Caledonia/20/99
• The NAs of current H1N1 viruses are similar antigenically and genetically to the N1 of A/New Caledonia/20/99
• The NAs of current H1N2 viruses are similar to to those of currently circulating H3N2 viruses
INFLUENZA A(H3N2) VIRUSES
HEMAGGLUTINATION INHIBITION REACTIONS OF INFLUENZA H3 VIRUSES
STRAIN DESIGNATION REFERENCE FERRET ANTISERAA B C D E F Date Passage
REFERENCE ANTIGENS SYD/5 MOS/10 PN/2007 HK/1550 NY/55 FUJ/411 collected
1 A/SYDNEY/05/97 640 10 320 320 640 40 06/23/97 CK2E2/E22 A/MOSCOW/10/99 320 640 320 320 640 40 01/15/99 E2/E23 A/PANAMA/2007/99* 160 160 320 320 640 80 07/12/99 E54 A/HONG KONG/1550/2002 640 320 640 640 1280 80 01/19/02 E55 A/NEW YORK/55/2001 320 320 640 320 1280 20 11/22/01 E46 A/GUANGZHOU/405/2002 40 40 160 160 160 1280 05/21/02 C2/C4
TEST ANTIGENS
7 A/NEW JERSEY/04/2002 640 1280 640 1280 1280 160 11/04/02 E28 A/THAILAND/1170/02 320 320 640 640 1280 160 10/21/02 X/C19 A/EGYPT/919441/2002 320 1280 640 640 1280 80 11/07/02 C2/C1
10 A/DAKAR/50/02 320 320 640 320 1280 80 10/30/02 CXC1/C111 A/EGYPT/919441/2002 320 640 640 640 1280 80 11/07/02 C2/C112 A/NEW JERSEY/4/2002* 160 320 320 640 640 n.d. 11/04/02 X/C413 A/ALASKA/4/2002 160 160 320 320 320 1280 12/02/02 X/C114 A/THAILAND/1169/2002 160 640 320 320 640 160 10/17/02 X/C115 A/ALASKA/4/2002 160 160 320 320 320 1280 12/02/02 X/C116 A/TEXAS/53/2002 160 160 320 320 320 2560 12/18/02 M1/C117 A/ENGLAND/455/2002 320 160 320 320 640 320 12/30/02 C1/C218 A/HAWAII/20/2002 80 160 160 320 160 640 12/04/02 C1/C219 A/GUAM/228/2002* 80 320 160 640 320 n.d. 10/26/02 X/C220 A/OSAKA/c70/2002 40 80 80 320 160 640 11/15/02 C2/C121 A/BEIJING/301/2002 40 160 80 80 160 640 12/20/02 C1/C122 A/KOREA/770/2002* 40 80 80 160 80 n.d. 12/02/02 X/C323 A/OSAKA-C/70/02 40 160 80 320 160 640 11/15/02 C2/C124 A/MEMPHIS/3/2003 40 40 80 80 80 320 01/21/03 C1/C125 A/EGYPT/919505/2002 40 80 80 320 160 80 11/16/02 C1/C226 A/BEIJING/290/2002 20 160 40 80 80 320 12/19/02 C1/C127 A/SHIGA/41/02 20 80 40 160 80 80 11/25/02 C1/C128 A/HAWAII/14/2002 20 40 40 40 40 640 12/24/02 M2/C1
* Serology antigens Courier - changes at aa 155+156
Influenza A(H3N2) Isolates Characterized by CDC
U.S.A. North America
Europe Asia Cent/So America
Africa, Australia,
New Zealand
Total (%)
April 2002 - September 2002
A/Panama/2007/99-like 15 1 3 108 27 7 161 (89%)
A/Panama/2007/99-like (low) 8 3 9 20 (11%)
Total 181
October 2002 - February 2003
A/Panama/2007/99-like 25 4 4 37 7 77 (70%)
A/Panama/2007/99-like (low) 8 24 1 33 (30%)
Total 110
Total 48 5 7 177 30 24 291 Preliminary Data 02/18/2003
Moscow/5/2000 #
Panama/2007/99 # **Fujian/140/2000 #
Beijing/144/2001Hong Kong/1550/2002 #
Moscow/10/99 #Sydney/5/97 #
R 50 GE 83 KV 202 I
W 222 RG 225 D
10 nucleotides
NIMR-Madagascar/66213/2002New York/28/2002
Aus-Victoria/241/2002Hawaii/4/2002
New York/55/2001 (LR)Utah/6/2002
NIID-Fukuoka/15/2002Aus-Sydney/23/2002
Hawaii/11/2002Louisiana/2/2002
New York/21/2002England/449/2002
North Carolina/8/2002Chile/6416/2001 #
Turkey/1035/2002NIMR-Dakar/50/2002 **
Brazil/1727/2002 (LR) #Brazil/2458/2002
Connecticut/1/2002Illinois/1/2002
Texas/4/2002Aus-Bangkok/109/2002 (LR) #
Washington/3/2002Wisconsin/17/2001Oklahoma/2/2002
Arizona/1/2002England/1/2003
NIID-Akita/69/2002 #
A 106 VN 144 D
A 304 P
Aus-Brisbane/5/2002 (LR) #NIID-Hyogo/3/2002
Aus-Perth/200/2002 (LR) #
Zhejiang/8/2002 (LR)India/25502/2002
Hubei/61/2002 (LR)Guangzhou/405/2002
Q 156 H
L 25 IH 75 QH 155 T
A 131 T
Hawaii/13/2002Aus-Taiwan/8/2002
NIID-Shiga/41/2002Can-Canada/rv6222/2002
Aus-Singapore/44/2002 (LR)Hong Kong/1554/2002
Hong Kong/1143/2002 (LR)Philippines/160283/2002 (LR)
Taiwan/1521/2002 (LR)Guam/228/2002 (LR)NIMR-Switzerland/7494/2002
New Jersey/4/2002 (LR) **NIMR-Egypt/151/2002
Beijing/178/2002 (LR)Fujian/411/2002 **Anhui/550/2002 (LR)
Beijing/301/2002 (LR)
Japan/910/2002 (LR)Alaska/4/2002California/9/2002Korea/770/2002 (LR)Hunan/407/2002
Hawaii/19/2002 (LR)Massachusetts/1/2003 (LR)
NIID-Toyama/29/2002PHLS-England/448/2002 (LR)
Memphis/4/2003 (LR)Memphis/1/2003 (LR)
Washington/3/2003NIID-Osaka-c/70/2002
NIID-Ishikawa/102/2002 **Georgia/1/2003 (LR)
BAFB-Korea/172/2003
Vaccine StrainEgg-Grown Isolate #Serology Antigen **Low Reactor (LR)
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA A(H3) HA1 GENES
NEURAMINIDASE INHIBITION TEST OF INFLUENZA N2 VIRUSES
STRAIN DESIGNATION FERRET ANTISERAA B C Date
REFERENCE ANIGENS PN/2007/99 Chile/6416/01 Shzh/499/00 collected
1 A/Panama/2007/99 (H3N2) 320 80 80 07/12/992 A/Chile/6416/2001(H3N2) 160 320 160 06/14/013 A/Shenzhen/499/2001(H3N2) 320 80 320 05/22/00
TEST ANIGENS
4 A/New York/28/2002 (H3N2) 320 320 320 10/12/025 A/Fujian/411/2002 (H3N2) 160 160 160 08/11/02
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA A(N2) NA GENESWuhan/396/2001
Wuhan/388/2001CNIC/114/2001Hong Kong/1307/2001
Guangzhou/1191/2001Singapore/54/2001
Shenzhen/499/2000#Hong Kong/1269/2001
Singapore/41/2001Nepal/1610/2001
Singapore/15/2001*Thailand/80891/2001
Hawaii/23/2001Wisconsin/12/2001
nimr-Moscow/10/2001#Hong Kong/762/2001*
Hong Kong/648/2001*#Hawaii/21/2001*Philippine/78890/2001*
Hawaii/29/2001Alaska/14/2001*
Alaska/8/2001Chile/6416/2001*#
Argentina/302/2001Argentina/10/2001
Argentina/3758/2001#Argentina/3759/2001*#
Massachusetts/2/2001North Carolina/1/2001
South Australia/102/2001*Florida/6/2001
Panama/2007/99*#Sydney/5/97
A18S, L23F, V307I
V30T, C42F
G414S
S332F, Q432E
K172R
10 nucleotides*Serology antigen# Egg isolate
Vaccine Strain
Summary: Influenza A(H3N2) Viruses
• H3N2 viruses have caused recent outbreaks in Japan, Korea and China
• An increasing proportion of recent H3N2 isolates are not well inhibited by post-infecton and post-immunization antiserum
• H3N2 viruses with aa changes at 155 and 156 (Site B) tend to be poorly inhibited by antibodies to the vaccine virus
• Low reacting viruses with aa changes at 155 and 156 have been detected in Asia, Europe and the Americas
INFLUENZA B VIRUSES
HEMAGGLUTINATION INHIBITION REACTIONS OF INFLUENZA TYPE B VIRUSES
STRAIN DESIGNATION REFERENCE FERRET ANTISERAA B C D E Date
REFERENCE ANTIGENS SIC/379 SHI/15 SHA/07 HK/330 BRI/32 collected Passage HA-NA
1 B/SICHUAN/379/99 640 640 20 5 40 12/02/99 E2/E4 Sic-Sic2 B/SHIZUOKA/15/2001 320 320 10 5 10 01/17/01 E3/E2 Sic-Sic3 B/SHANDONG/7/97* 10 5 640 320 640 11/03/97 E4/E3 SH-Vic4 B/HONG KONG/330/2001* 10 5 320 320 640 04/09/01 E3 HK-Vic5 B/BRISBANE/32/2002* 10 5 320 160 640 07/02/02 E2/E4 SH-Sic
TEST ANTIGENS
6 B/SHANGHAI/361/2002* 640 640 20 20 20 06/12/02 E2/E1 Sic-Sic7 B/TEXAS/04/2003 80 160 5 5 5 01/14/03 M1/C1 Har-Sic8 B/SHANGHAI/720/2002 320 160 20 5 10 11/27/02 C1E1/E3 Har-Sic9 B/HONG KONG/1434/2002* 10 5 640 640 1280 01/15/02 E4 HK-Vic10 B/OKLAHOMA/03/2002 5 5 160 320 640 11/25/02 X1/C1 SH-Sic11 B/MISSOURI/10/2003 20 5 320 320 1280 01/09/03 X/C1 SH-Sic12 B/IOWA/03/2003 5 5 160 320 640 01/24/03 X1/C1 SH-Sic13 B/NEVADA/05/2002 10 5 320 320 640 12/17/02 X/C2 SH-Sic14 B/GUANGZHOU/992/2002 5 5 320 320 640 11/20/02 C2/C2 SH-Sic15 B/JAPAN/147/2002 5 5 160 160 640 12/24/02 X/C1 HK-Sic16 B/NEW JERSEY/01/2003 5 5 160 160 320 01/27/03 MX/C1 SH-Sic17 B/SOUTH DAKOTA/01/2003 5 5 160 160 320 01/14/03 M1/C1 SH-Sic18 B/TIANJIN/130/2002 5 5 160 160 640 12/18/02 C1/C1 SH-Sic19 B/TIANJIN/192/2002 10 5 160 160 640 12/16/02 C1/C1 SH-Sic20 B/TIANJIN/189/2002 5 5 160 160 640 12/17/02 C1/C1 SH-Sic21 B/BEIJING/171/2002 5 5 80 160 320 11/22/02 C1/C1 SH-Sic22 B/NEVADA/01/2003 5 5 80 80 160 01/18/03 M1/C1 SH-Sic23 B/NEW YORK/01/2003 5 5 80 80 320 01/04/03 X1/C1 SH-Sic24 B/TEXAS/07/2003 5 5 80 80 320 01/21/03 M1/C1 SH-Sic25 B/WASHINGTON/01/2003 5 5 80 80 160 01/15/03 X/C1 SH-Sic26 B/IOWA/02/2003 5 5 80 80 320 01/24/03 X1/C1 SH-Sic27 B/S.CAROLINA/01/2003 5 5 80 80 320 01/16/03 X1/C1 SH-Sic28 B/TEXAS/57/2002* 5 5 160 80 320 12/04/02 M1/C1 SH-Sic
* Serology antigens
Influenza B Isolates Characterized by CDC
U.S.A. North America
Europe Asia Cent/So America
Africa, Australia,
New Zealand
Total (%)
April 2002 - September 2002
B/Hong Kong/330/2001-like 56 22 57 17 152 (43%)
B/HK/330/2001-like (low) 41 68 48 16 173 (49%)
B/Sichuan/379/99-like 2 10 2 14 (4%)
B/Sichuan/379/99 (low) 1 6 8 15 (4%)
Total 354
October 2002 - February 2003
B/Hong Kong/330/2001-like 39 3 56 1 99 (54%)
B/HK/330/2001-like (low) 50 1 21 72 (40%)
B/Sichuan/379/99-like 2 4 6 (3%)
B/Sichuan/379/99 (low) 1 3 2 6 (3%)
Total 183
Total 190 1 3 188 121 34 537
Preliminary Data 02/18/2003
Currently Circulating Type B HA Lineages
Hong Kong/330/2001
25 nucleotides
Victoria Lineage
Yamagata Lineage
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA B HA1 GENES (YAMAGATA LINEAGE)
Egg-Grown Isolate #Serology Antigen **Low Reactor (LR)
NIID-Fukushima/24/2002Harbin/7/94 #
Taiwan/143999/2002 (LR)NIMR-Madagascar/65186/2002
Moscow/16/2002 #NIID-Astrakhan/10/2002 #
California/2/2002NIID-Ulan Ude/4/2002 #Russia/4/2002 (LR) #
NIID-Yunnan/406/2001 #Colorado/3/2002 (LR)
Fujian/407/2001 #NIMR-St. Petersburg/1/2002NIMR-Finland/141/2002
Nevada/1/2002NIMR-Hong Kong/293/2002
NIID-Yunnan/8/2002 #Yunnan/9/2002 (LR) #
Yunnan/163/2002 #Aus-Bangkok/60/2002
Ohio/2/2002Brazil/2459/2002 (LR)Gaughwa/19/2002 (LR)
Aus-Sydney/200/2002Aus-Sydney/3/2002
NIID-Sendai/h1754/2001 (LR) #**NIPH-Oslo/668/2002
NIID-Akita/2/2002 #NIID-Sapporo/7/2002 (LR)
Hong Kong/1470/2002 (LR) #NIPH-Oslo/1870/2002
Tennessee/4/2002 (LR)Arizona/4/2002 (LR)
Chile/3162/2002 (LR) #New York/44/2002
NIID-Shizuoka/15/2001 #**NIMR-Lazio/1/2002
NIMR-Lyon/125/2002Peru/3132/2002 (LR)
NIMR-Barcelona/460/2002Colombia/3438/2002
Mexico/418/2001 (LR)Fujian/141/2001 #
Aus-Victoria/504/2000 #NIID-Shizuoka/480/2000 #
NIMR-Perm/3/2002Sichuan/379/99 #**
Yamanashi/166/98 #Beijing/184/93 #
R 69 GT 121 AR 136 KN 165 DT 182 AK 183 N
L 58 FN 126 D
H 40 Y
K 48 RT 168 N
N 126 D
Shanghai/361/2002 #
10 nucleotides
Thailand/163343/2002 (LR)
Aus-Brisbane/17/2002 #Iowa/3/2002 (LR) #
Idaho/4/2002 (LR)Aus-Auckland/14/2002
Aus-Brisbane/32/2002 (LR) #**Aus-Brisbane/28/2002 #
Aus-Perth/82/2002NIMR-Lisbon/190/2002
Louisiana/1/2002 (LR)NIMR-Madagascar/67860/2002 #**
Tianjin/130/2002Oman/16291/2001 (LR)
California/5/2002Taiwan/1519/2002 (LR)
Brazil/1730/2002 #Nevada/5/2002
New York/43/2002Texas/57/2002 (LR) **
Wisconsin/1/2003Missouri/12/2002
NIMR-Hong Kong/302/2002Hawaii/5/2002 (LR)Hong Kong/1351/2002 #Panama/486105/2002
Chile/13677/2002 #Mexico/963/2002 (LR)
Argentina/mc16/2002 (LR)Brazil/1733/2002 (LR) #Guatemala/20/2002 (LR)
New Hampshire/1/2002Beijing/243/97 #
Shandong/7/97 #**Guam/345/2002
NIID-Saitama/22/2002 #NIID-Sendai/h1023/2002 #NIID-Tokyo/127/2002 #NIID-Shiga/20/2002 #
Hong Kong/1115/2002 (LR) #Hong Kong/167/2002 #Hong Kong/1345/2002 #Hong Kong/1434/2002 #**
Wisconsin/7/2002Guangzhou/332/2002 (LR) #
Taiwan/1507/2002 (LR)Hong Kong/330/2001 #**
Hong Kong/335/2001 #NIID-Akita/27/2001 #
Taiwan/217/97
South Carolina/8/2002 (LR)I 121 T
H 116 RE 121 ND 164 E
5 nucleotides
Vaccine StrainEgg-Grown Isolate #Serology Antigen **Low Reactor (LR)
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA B HA1 GENES (VICTORIA LINEAGE)
Restriction Analysis of Influenza B Isolates
U.S.A. North America
Europe Asia Cent/So America
Africa, Australia,
New Zealand
Total (%)
April 2002 - September 2002
B/Yamanashi/166/98/ B/Sichuan/379/99 lineage
3
8
6
17 (4%)
B/Harbin/07/94 lineage 2 14 5 21 (5%)
B/Hong Kong/330/01 lineage 1 14 15 (4%)
B/Oman/16296/2001 lineage 103 85 119 27 334 (87%)
Total 387
October 2003 - March 2003
B/Yamanashi/166/98/ B/Sichuan/379/99 lineage
1
1 (0.5%)
B/Harbin/07/94 lineage 1 6 7 (4%)
B/Hong Kong/330/01 lineage 2 46 48 (26.5%)
B/Oman/16296/2001 lineage 57 1 3 59 4 1 125 (69%) 181
Total 181
Total 424 6 44 486 231 33 1224
Preliminary Data 02/18/2003
Neuraminidase Inhibition Test of Influenza B viruses
STRAIN DESIGNATION FERRET ANTISERAA B C D Date
REFERENCE ANTIGENS Sic/379 Bris/32 SH/7 HK/330 collected
1 B/Sichuan/379/99 (Sic-Sic) 640 480 20 80 12/02/992 B/Brisbane/32/2002 (SH-Sic) 320 1280 40 320 07/02/023 B/Shandong/7/97(SH-Vic) 160 160 1280 2560 11/03/974 B/Hong Kong/330/02 (HK-Vic) 80 320 640 1280 04/09/01
TEST ANTIGENS
5 B/Texas/53/2002 (SH-Sic) 240 480 120 80 11/19/026 B/Philippines/198389/2002 (SH-Sic) 640 480 20 160 11/07/027 B/Guangzhou/332/2002 (HK-Vic) 80 160 320 640 08/29/02
Victoria/504/2000*Shizuoka/480/2000
Alaska/16/2000Shenzhen/804/2001#
Brazil/956/2001*#Hong Kong/692/2001*
nimr-Yamanashi/166/98Brazil/952/2001#
P42S, R69E
Niid-Shizuoka/15/2001*#E148G
Texas/22/20001*
Argentina/132/2001Argentina/69/2001
Wuhan/2/2001#Johannesburg/69/2001*#
Fujian/407/2001Wuhan/356/2001#
Sichuan/317/2001*#Sichuan/776/2001#
Osaka/18/2001Shenzhen/306/2001#
Harbin/7/94
D329N
P42Q, N219K, D392E
Hawaii/36/2001Hawaii/10/2001#
Hong Kong/28/2001Hong Kong/6/2001
Hong Kong/330/2001*Canada/464/2001
Hong Kong/22/2001Bangkok/34/99Bangkok/54/99
Shandong/7/97Yamagata/16/88
M50T, C54S, V60F, R436K
*Serology Antigen# Egg isolate
10 nucleotides
Vaccine Strain
Sichuan/379/99*#Johannesburg/5/99
EVOLUTIONARY RELATIONSHIPS AMONG INFLUENZA B NA GENES
Summary: Influenza B Viruses
• Influenza B viruses are predominating in the U.S. and much of Europe during the current season
• Influenza B viruses on the “Victoria lineage have predominated worldwide; B viruses on the Sichuan lineage were isolated infrequently
• Most recent influenza B viruses have NAs most closely related antigenically and genetically to that of the B/Sichuan ref. Virus
• The influenza B viruses have remained stable genetically and antigenically since last September